Business Context and Reporting Period
LifeStance Health Group, Inc. filed this Form 8-K on December 19, 2024, to report the entry into a new material definitive agreement and the termination of a prior credit facility. The company is a Delaware corporation headquartered in Scottsdale, Arizona, with common stock trading on The Nasdaq Stock Market under the symbol LFST.
Key Financial Metrics and Debt Structure
The filing details a significant refinancing transaction executed on December 19, 2024:
- Term Loan Facility: A senior secured term loan of $290.0 million was funded on the closing date.
- Revolving Facility: A new senior secured revolving loan facility with commitments of up to $100.0 million was established.
- Interest Rates: Loans bear interest at adjusted term SOFR plus 3.00% (subject to stepdowns) or an alternate base rate plus 2.00% (subject to stepdowns).
- Fees: A quarterly undrawn commitment fee of 0.45% per annum applies to the Revolving Facility.
- Maturity: Both facilities mature on the fifth anniversary of the closing date (December 2029).
- Collateral: Obligations are secured by substantially all assets of the Borrower, Holdings, and subsidiary guarantors.
The filing does not provide specific revenue, profit, cash flow, or margin data for the reporting period.
Material Changes Versus Prior Period
The primary material change is the replacement of the company's existing debt structure:
- Termination: The "Existing Credit Agreement" dated May 4, 2022, was terminated on the closing date.
- Refinancing: Proceeds from the new $290.0 million Term Loan were used to repay all outstanding loans and commitments under the 2022 agreement.
- Capacity Increase: The new agreement establishes a $100.0 million revolving facility, providing additional liquidity compared to the terminated agreement.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the availability of commitments under the 2024 Credit Agreement. Management highlights several risks and uncertainties, including:
- Market conditions and funding conditions related to the new credit agreement.
- The potential adverse effect of existing indebtedness on business and growth prospects.
- Compliance with affirmative, negative, and financial covenants contained in the new agreement.
The company explicitly states it does not undertake to update forward-looking statements to reflect changes in expectations or circumstances.
Investor Verification Checklist
- Verify the specific leverage-based metrics required to achieve interest rate stepdowns.
- Review the full text of the 2024 Credit Agreement (to be filed as an exhibit to the 2024 Form 10-K) for detailed financial covenants and events of default.
- Confirm the exact amount of outstanding debt remaining after the repayment of the 2022 facility.
- Assess the impact of the new interest rate structure (SOFR + 3.00%) on future interest expense compared to the prior agreement.